Drug Profile
S 36527
Alternative Names: S-36527Latest Information Update: 04 Apr 2007
Price :
$50
*
At a glance
- Originator Kaken Pharmaceutical
- Class Antiasthmatics
- Mechanism of Action Leukotriene D4 receptor antagonists; Thromboxane A2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 04 Apr 2007 Discontinued for Asthma in Japan (unspecified route)
- 28 Jun 2002 No development reported for Asthma in Japan (unspecified route)
- 29 Oct 1999 S 36527 is available for licensing (http://www.kaken.co.jp)